ERBB2 and breast carcinoma: GOF mup53 has been demonstrated to affect multiple oncogenic signaling pathways, upregulating various stem cell markers in colorectal cancer cells [97] and increasing human epidermal growth factor receptor 2 (HER2) expression in breast cancer cells [98].